Authors as listed in the European Journal of Neuroscience record, 2018-09-25: Rat study in the 6-hydroxydopamine Parkinson model showing that chronic co-administration of methylene blue with L-DOPA reduced L-DOPA-induced dyskinesia; preclinical only, with no human Parkinson's data.
methylene blue was able to reduce L-DOPA-induced dyskinesia incidence when chronically co-administered with L-DOPA during
abstract
Authors as listed in the European Journal of Neuroscience record, 2018-09-25: Rat study in the 6-hydroxydopamine Parkinson model showing that chronic co-administration of methylene blue with L-DOPA reduced L-DOPA-induced dyskinesia; preclinical only, with no human Parkinson's data. Study type: animal (rat, 6-OHDA-lesioned) pharmacology experiment. N not stated in abstract. Country: not stated in abstract (European laboratory). Dose/route/schedule: methylene blue co-administered with L-DOPA for 3 weeks; dose not stated in abstract. Comparator: L-DOPA alone and the selective guanylyl cyclase inhibitor ODQ. Funder/conflicts: not stated in abstract. Bearing reflects that the Parkinson's rationale rests on animal work: no registered or published human methylene blue trial in Parkinson's disease was located (see flag report). Study type: animal.
